Preliminary ProspectusI just finished reading the Preliminary Prospectus. The final version is not available yet.
The final one will have bullets replaced by numbers for issue price, warrant exercise price and cash available after the transaction completes. It may also have additional clarity on some issues if the OSC requests it during their review. So we will have to re-read the document when the final version is issued.
But the preliminary version has exceptional clarity for a Bioniche document. Good stuff, Dr. Berendt. I look forward to reading a much-improved annual report this year.
Be sure to read the never-before-published detail on Phase 3a results. They also have some data on the trial that Endo ran and terminated for lack of recruitment success.